Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer

四维表观基因组重塑：对乳腺癌内分泌抵抗的影响

• 批准号: nhmrc : 1128916
• 负责人: A/Pr Elgene Lim
• 金额: $ 56.54万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dimensional-epigenome-remodelling-breast-cancer/948304
• 关键词: Four; dimensional; epigenome; remodelling; implications

Patients with estrogen receptor positive breast cancer receive endocrine therapy, however half fail to respond and relapse. Endocrine resistant breast cancer currently represents the most significant challenge to breast cancer treatment. We suggest that three-dimensional epigenetic remodelling is an underlying mechanism that determines endocrine sensitivity that we will exploit as a novel therapeutic strategy to effectively treat patents with recurrent disease.

雌激素受体阳性的乳腺癌患者接受内分泌治疗，但有一半无效并复发。内分泌抵抗型乳腺癌目前是乳腺癌治疗面临的最大挑战。我们认为，三维表观遗传重塑是决定内分泌敏感性的潜在机制，我们将利用这一机制作为一种新的治疗策略，有效地治疗复发疾病患者。